Hemab Therapeutics closed a $157 million financing to advance a pipeline targeting underserved bleeding disorders, including two clinical-stage candidates. The round was led by Sofinnova Partners with participation from Novo Holdings and crossover investors, and will fund a pivotal trial for sutacimig and further development of HMB-002. CEO Benny Sorensen framed the raise as a step toward assembling a focused coagulation company; sutacimig is slated for a pivotal study in Glanzmann thrombasthenia next year while HMB-002 has shown early proof-of-mechanism. The financing underscores renewed investor interest in niche hematology indications that larger players have historically deprioritized. The round also signals a shift in capital allocation: investors are willing to back engineered antibody and biologic approaches for small patient populations where clinical differentiation and durable benefit can support premium pricing.